Skip to Content

Apoquel 5.4 mg tablets (Canada)

This page contains information on Apoquel 5.4 mg tablets for veterinary use.
The information provided typically includes the following:
  • Apoquel 5.4 mg tablets Indications
  • Warnings and cautions for Apoquel 5.4 mg tablets
  • Direction and dosage information for Apoquel 5.4 mg tablets

Apoquel 5.4 mg tablets

This treatment applies to the following species:
Manufacturer: Zoetis

DIN 02427885

DIN 02427893

DIN 02427907

oclacitinib tablets

3.6 mg 5.4 mg 16 mg

Veterinary Use Only

Janus Kinase Inhibitor for dogs

Description

APOQUEL™ (oclacitinib maleate) is a synthetic Janus Kinase inhibitor. The chemical name of the active ingredient in APOQUEL tablets is N-methyl[trans-4-(methyl-7H-pyrrolo[2,3-d] pyrimidin-4-ylamino) cyclohexyl]methanesulfonamide (2Z)-2-butenedioate.

The chemical structure of oclacitinib maleate is:

Apoquel 5.4 mg tablets Indications

For the control of pruritus associated with allergic dermatitis and for the control of atopic dermatitis in dogs at least 12 months of age.

Dosage and Administration

The dose of APOQUEL tablets is 0.4 mg/kg to 0.6 mg oclacitinib /kg body weight, administered orally, twice daily for up to 14 days, and then administered once daily for maintenance therapy. APOQUEL tablets may be administered with or without food.

Dosing Chart

Dog body weight (kg)

3.6 mg tablets

5.4 mg tablets

16 mg tablets

3 - 4.4

0.5

 

 

4.5 - 5.9

 

0.5

 

6 - 8.9

1

 

 

9 - 13.4

 

1

 

13.5 - 19.9

 

 

0.5

20 - 26.9

 

2

 

27 - 39.9

 

 

1

40 - 54.9

 

 

1.5

55 - 80

 

 

2

Contraindications

APOQUEL tablets should not be given to dogs with known or suspected allergy or intolerance to oclacitinib maleate or any other components of this product.

APOQUEL tablets are not for use in dogs less than 12 months of age (see Animal Safety).

APOQUEL tablets are not for use in dogs with serious infections, evidence of immune suppression or evidence of malignant neoplasia.

APOQUEL tablets are not for use in breeding dogs, pregnant or lactating bitches.

Cautions:

The safe use of APOQUEL tablets has not been evaluated in dogs less than 3 kg (6.6 lbs) body weight.

The use of APOQUEL tablets has not been evaluated in combination with glucocorticoids, cyclosporine, or other immunosuppressive agents.

APOQUEL tablets modulate the immune system. Active infections should have resolved before starting therapy with APOQUEL tablets. Dogs receiving APOQUEL tablets should be monitored for signs and symptoms of infection, including demodicosis and neoplasia.

Given the potential for effects on certain clinical pathology parameters, periodic monitoring with complete blood counts and serum biochemistry is recommended when dogs are on treatment long-term.

Warnings: Not for use in humans. Keep out of reach of children. Wash hands immediately after handling the tablets. In case of accidental eye contact, flush immediately with water or saline for at least 15 minutes and then seek medical attention. In case of accidental ingestion, seek medical attention immediately.

Adverse Reactions:

Control of Pruritus Associated with Allergic Dermatitis

In a masked field study to assess the efficacy and safety of APOQUEL tablets for the control of pruritus associated with allergic dermatitis in dogs, 216 dogs treated with APOQUEL tablets and 220 dogs treated with placebo (vehicle control) were evaluated for safety. During the 30-day study, there were no fatalities and no adverse reactions requiring hospital care. Adverse reactions reported (and percent of dogs affected) are found in Table 1.

Table 1: Adverse reactions observed in pruritus study up to day 7

 

APOQUEL tablets

(n=216)

Placebo

(n=220)

Diarrhea

2.3%

0.9%

Vomiting

2.3%

1.8%

Anorexia

1.4%

0%

New cutaneous or subcutaneous lumps

1.0%

0%

Lethargy

1.8%

1.4%

Polydipsia

1.4%

0%

In most of these cases, signs spontaneously resolved with continued dosing.

Five APOQUEL tablets group dogs were withdrawn from study because of: darkening areas of skin and fur (1 dog); diarrhea (1 dog); fever, lethargy and cystitis (1 dog); an inflamed footpad and vomiting (1 dog); and diarrhea, vomiting, and lethargy (1 dog).

Dogs in the APOQUEL tablets group had a slight decrease in mean white blood cell counts (neutrophil, eosinophil, and monocyte counts) that remained within the normal reference range. Mean lymphocyte count for dogs in the APOQUEL tablets group increased at Day 7, but returned to pretreatment levels by study end without a break in APOQUEL tablets administration. Serum cholesterol increased in 25% of APOQUEL tablets group dogs, but mean cholesterol remained within the reference range.

Control of Atopic Dermatitis

In a masked field study to assess the efficacy and safety of APOQUEL tablets for the control of atopic dermatitis in dogs, 152 dogs treated with APOQUEL tablets and 147 dogs treated with placebo (vehicle control) were evaluated for safety. The majority of dogs in the placebo group withdrew from the 112-day study by Day 16. Adverse reactions reported (and percent of dogs affected) are found in Table 2.

Table 2: Adverse reactions observed in atopic dermatitis study up to day 16

 

APOQUEL tablets

(n=152)

Placebo

(n=147)

Diarrhea

4.6%

3.4%

Vomiting

3.9%

4.1%

Anorexia

2.6%

0%

New cutaneous or subcutaneous lumps

2.6%

2.7%

Lethargy

2.0%

1.4%

Polydipsia

0.7%

1.4%

In most cases, diarrhea, vomiting, anorexia, and lethargy spontaneously resolved with continued dosing.

Dogs on APOQUEL tablets had decreased leukocytes (neutrophil, eosinophil, and monocyte counts) and serum globulin, and increased cholesterol and lipase compared to the placebo group but group means remained within the normal range. Mean lymphocyte counts were transiently increased at Day 14 in the APOQUEL tablets group.

Dogs that withdrew from the masked field study could enter an unmasked study where all dogs received APOQUEL tablets. Between the masked and unmasked study, 283 dogs received at least one dose of APOQUEL tablets. Of these 283 dogs, two dogs were withdrawn from study due to suspected treatment-related adverse reactions: one dog that had an intense flare-up of dermatitis and severe secondary pyoderma after 19 days of APOQUEL tablets administration, and one dog that developed generalized demodicosis after 28 days of APOQUEL tablets administration. Two other dogs on APOQUEL tablets were withdrawn from study due to suspected or confirmed malignant neoplasia and subsequently euthanized, including one dog that developed signs associated with a heart base mass after 21 days of APOQUEL tablets administration, and one dog that developed a Grade III mast cell tumor after 60 days of APOQUEL tablets administration.

One of the 147 dogs in the placebo group developed a Grade I mast cell tumor and was withdrawn from the masked study. Additional dogs receiving APOQUEL tablets were hospitalized for diagnosis and treatment of pneumonia (one dog), transient bloody vomiting and stool (one dog), and cystitis with urolithiasis (one dog).

In the 283 dogs that received APOQUEL tablets, the following additional clinical signs were reported after beginning APOQUEL tablets (percentage of dogs with at least one report of the clinical sign as a non-pre-existing finding): pyoderma (12.0%), non-specified dermal lumps (12.0%), otitis (9.9%), vomiting (9.2%), diarrhea (6.0%), histiocytoma (3.9%), cystitis (3.5%), anorexia (3.2%), lethargy (2.8%), yeast skin infections (2.5%), pododermatitis (2.5%), lipoma (2.1%), polydipsia (1.4%), lymphadenopathy (1.1%), nausea (1.1%), increased appetite (1.1%), aggression (1.1%), and weight loss (0.7%).

Continuation Field Study

After completing APOQUEL tablets field studies, 239 dogs enrolled in an unmasked (no placebo control), continuation therapy study receiving APOQUEL tablets for an unrestricted period of time. Mean time on this study was 372 days (range 1 to 610 days).

Of these 239 dogs, one dog developed demodicosis following 273 days of APOQUEL tablets administration. One dog developed dermal pigmented viral plaques following 266 days of APOQUEL tablets administration. One dog developed a moderately severe bronchopneumonia after 272 days of APOQUEL tablets administration; this infection resolved with antimicrobial treatment and temporary discontinuation of APOQUEL tablets. One dog was euthanized after developing abdominal ascites and pleural effusion of unknown etiology after 450 days of APOQUEL tablets administration. Six dogs were euthanized because of suspected malignant neoplasms: including thoracic metastatic, abdominal metastatic, splenic, frontal sinus, and intracranial neoplasms, and transitional cell carcinoma after 17, 120, 175, 49, 141, and 286 days of APOQUEL tablets administration, respectively. Two dogs each developed a Grade II mast cell tumor after 52 and 91 days of APOQUEL tablets administration, respectively. One dog developed low grade B-cell lymphoma after 392 days of APOQUEL tablets administration. Two dogs each developed an apocrine gland adenocarcinoma (one dermal, one anal sac) after approximately 210 and 320 days of APOQUEL tablets administration, respectively. One dog developed a low grade oral spindle cell sarcoma after 320 days of APOQUEL tablets administration.

Clinical Pharmacology

Mechanism of Action

Oclacitinib inhibits the function of a variety of pruritogenic cytokines and pro-inflammatory cytokines, as well as cytokines involved in allergy that are dependent on JAK1 or JAK3 enzyme activity, whereas it has little effect on cytokines involved in hematopoiesis that are dependent on JAK2. Oclacitinib is not a corticosteroid or an antihistamine.

Pharmacokinetics

In dogs, oclacitinib maleate is rapidly and well absorbed following oral administration, with mean time to peak plasma concentrations (Tmax) of less than 1 hour. Following oral administration of 0.4-0.6 mg oclacitinib/kg to 24 dogs, the mean (90% confidence limits [CL]) maximum concentration (Cmax) was 324 (281, 372) ng/mL and the mean area under the plasma concentration-time curve from 0 and extrapolated to infinity (AUC0-inf) was 1890 (1690, 2110) ng•hr/mL. The prandial state of dogs does not significantly affect the rate or extent of absorption. The absolute bioavailability of oclacitinib maleate was 89%.

Oclacitinib has low protein binding with 66.3- 69.7% bound in fortified canine plasma at nominal concentrations ranging from 10-1000 ng/mL. The apparent mean (95% CL) volume of distribution at steady-state was 942 (870, 1014) mL/kg body weight.

Oclacitinib is metabolized in the dog to multiple metabolites and one major oxidative metabolite was identified in plasma and urine. Overall the major clearance route is metabolism with minor contributions from renal and biliary elimination. Inhibition of canine cytochrome P450 enzymes by oclacitinib is minimal; the inhibitory concentrations (IC50s) are 50 fold greater than the observed Cmax values at the use dose.

Mean (95% CL) total body oclacitinib clearance from plasma was low - 316 (237, 396) mL/h/ kg body weight (5.3 mL/min/kg body weight). Following IV and PO administration, the terminal t1/2 appeared similar with mean values of 3.5 (2.2, 4.7) and 4.1 (3.1, 5.2) hours, respectively.

Efficacy:

Control of Pruritus Associated with Allergic Dermatitis

A double-masked, 30-day, controlled study was conducted in the U.S. at 26 veterinary hospitals. The study enrolled 436 client-owned dogs with a history of allergic dermatitis attributed to one or more of the following conditions: atopic dermatitis, flea allergy, food allergy, contact allergy, and other/unspecified allergic dermatitis. Dogs were randomized to treatment with APOQUEL tablets (216 dogs: tablets administered at a dose of 0.4-0.6 mg/kg twice daily) or placebo (220 dogs: vehicle control, tablets administered twice daily). During the study, dogs could not be treated with other drugs that could affect the assessment of pruritus or dermal inflammation such as corticosteroids, anti-histamines, or cyclosporine. Treatment success for each dog was defined as at least a 2 cm decrease from baseline on a 10 cm visual analog scale (VAS) in pruritus, assessed by the Owner, on at least 5 of the 7 evaluation days. The estimated proportion of dogs with Treatment Success was greater and significantly different for the APOQUEL tablets group compared to the placebo group.

Owner-Assessed Pruritus VAS Treatment Success, Allergic Dermatitis

Efficacy Parameter

APOQUEL tablets

(n = 203)

Placebo

(n = 204)

P-value

Estimated Proportion of Dogs with Treatment Success

0.67

0.29

p<0.0001

After one week of treatment, 86.4% of APOQUEL tablets group dogs compared with 42.5% of placebo group dogs had achieved a 2 cm reduction on the 10 cm Owner-assessed pruritus VAS. On each of the 7 days, mean Owner-assessed pruritus VAS scores were lower in dogs in the APOQUEL tablets group (See Figure 1). Veterinarians used a 10 cm VAS scale to assess each dog’s dermatitis. After one week of treatment, the mean Veterinarian-assessed VAS dermatitis score for the dogs in the APOQUEL tablets group was lower at 2.2 cm (improved from a baseline value of 6.2 cm) compared with the placebo group mean score of 4.9 cm (from a baseline value of 6.2 cm). For dogs that continued APOQUEL tablets treatment beyond one week, the Veterinarian-assessed dermatitis scores continued to improve through study end at Day 30.

Figure 1: Owner Assessed Pruritus VAS Scores by treatment for Days 0-7

Control of Atopic Dermatitis

A double-masked, 112-day, controlled study was conducted in the U.S. at 18 veterinary hospitals. The study enrolled 299 client-owned dogs with atopic dermatitis. Dogs were randomized to treatment with APOQUEL tablets (152 dogs: tablets administered at a dose of 0.4-0.6 mg/kg per dose twice daily for 14 days and then once daily) or placebo (147 dogs: vehicle control, tablets administered on the same schedule). During the study, dogs could not be treated with other drugs that could affect the assessment of effectiveness, such as corticosteroids, anti-histamines, or cyclosporine. Treatment success for pruritus for each dog was defined as at least a 2 cm decrease from baseline on a 10 cm visual analog scale (VAS) in pruritus, assessed by the Owner, on Day 28. Treatment success for skin lesions was defined as a 50% decrease from the baseline Canine Atopic Dermatitis Extent and Severity Index (CADESI) score, assessed by the Veterinarian, on Day 28. The estimated proportion of dogs with Treatment Success in Owner-assessed pruritus VAS score and in Veterinarian-assessed CADESI score was greater and significantly different for the APOQUEL tablets group compared to the placebo group.

Estimated Proportion of Dogs with Treatment Success, Atopic Dermatitis

Efficacy Parameter

APOQUEL tablets

Placebo

P-value

Owner-Assessed Pruritus VAS

0.66

(n = 131)

0.04

(n = 133)

p<0.0001

Veterinarian-Assessed CADESI

0.49

(n = 134)

0.04

(n = 134)

p<0.0001

Compared to the placebo group, mean Owner-assessed pruritus VAS scores (on Days 1, 2, 7, 14, and 28) and Veterinarian-assessed CADESI scores (on Days 14 and 28) were lower (improved) in dogs in the APOQUEL tablets group. By Day 30, 86% (127/147) of the placebo group dogs and 15% (23/152) of the APOQUEL tablets group dogs withdrew from the masked study because of worsening clinical signs, and had the option to enroll in an unmasked study and receive APOQUEL tablets. For dogs that continued APOQUEL tablets treatment beyond one month, the mean Owner-assessed pruritus VAS scores and Veterinarian-assessed CADESI scores continued to improve through study end at Day 112.

Animal Safety:

Margin of Safety in 12 Month Old Dogs

APOQUEL tablets were administered to healthy, one-year-old Beagle dogs twice daily for 6 weeks, followed by once daily for 20 weeks, at 0.6 mg/kg (1X maximum exposure dose, 8 dogs), 1.8 mg/kg (3X, 8 dogs), and 3.0 mg/kg (5X, 8 dogs) oclacitinib for 26 weeks. Eight dogs received placebo (empty gelatin capsule) at the same dosage schedule. Clinical observations that were considered likely to be related to oclacitinib maleate included papillomas and a dose-dependent increase in the number and frequency of interdigital furunculosis (cysts) on one or more feet during the study. Additional clinical observations were primarily related to the interdigital furunculosis and included dermatitis (local alopecia, erythema, abrasions, scabbing/crusts, and edema of feet) and lymphadenopathy of peripheral nodes. Microscopic findings considered to be oclacitinib maleate-related included decreased cellularity (lymphoid) in Gut-Associated Lymphoid Tissue (GALT), spleen, thymus, cervical and mesenteric lymph node; and decreased cellularity of sternal and femoral bone marrow. Lymphoid hyperplasia and chronic active inflammation was seen in lymph nodes draining feet affected with interdigital furunculosis. Five oclacitinib maleate-treated dogs had microscopic evidence of mild interstitial pneumonia.

Clinical pathology findings considered to be oclacitinib maleate-related included mild, dose-dependent reduction in hemoglobin, hematocrit, and reticulocyte counts during the twice daily dosing period with decreases in the leukocyte subsets of lymphocytes, eosinophils, and basophils. Total proteins were decreased over time primarily due to the albumin fraction.

Vaccine Response Study

An adequate immune response (serology) to killed rabies (RV), modified live canine distemper virus (CDV), and modified live canine parvovirus (CPV) vaccination was achieved in eight 16-week old vaccine naïve puppies that were administered APOQUEL tablets at 1.8 mg/kg oclacitinib (3X maximum exposure dose) twice daily for 84 days. For modified live canine parainfluenza virus (CPI), < 80% (6 of 8) of the dogs achieved adequate serologic response. Clinical observations that were considered likely to be related to oclacitinib maleate treatment included enlarged lymph nodes, interdigital furunculosis, cysts, and pododermatitis. One APOQUEL tablets-treated dog (26-weeks-old) was euthanized on Day 74 after physical examination revealed the dog to be febrile, lethargic, with pale mucous membranes and frank blood in stool. Necropsy revealed pneumonia of short duration and evidence of chronic lymphadenitis of mesenteric lymph nodes. During the three month recovery phase to this study, one APOQUEL tablets-treated dog (32-weeks old) was euthanized on Day 28 due to clinical signs which included enlarged prescapular lymph nodes, bilateral epiphora, lethargy, mild dyspnea, and fever. The dog showed an elevated white blood cell (WBC) count. Necropsy revealed lesions consistent with sepsis secondary to immunosuppression. Bone marrow hyperplasia was consistent with response to sepsis.

Margin of Safety in 6 Month Old Dogs

A margin of safety study in 6-month-old dogs was discontinued after four months due to the development of bacterial pneumonia and generalized demodex mange infections in dogs in the high dose (3X and 5X) treatment groups, dosed at 1.8 and 3.0 mg/kg oclacitinib twice daily, for the entire study.

Storage

APOQUEL tablets should be stored at controlled room temperature between 20 to 25°C, with excursions between 15 to 40°C.

Presentation: APOQUEL tablets contain 3.6 mg, 5.4 mg, or 16 mg of oclacitinib (as oclacitinib maleate) per tablet. Each strength tablets are packaged in 20 and 100 count bottles. Each tablet is scored and marked with AQ and either an S, M, or L that correspond to the different tablet strengths on both sides. Not all pack sizes maybe marketed.

Zoetis and Apoquel are trademarks of Zoetis or its licensors, used under license by Zoetis Canada Inc.

Zoetis Canada Inc., Kirkland QC H9H 4M7

2520-17-0

NAC No.: 1198524.0

ZOETIS CANADA INC.
16,740 TRANS-CANADA HIGHWAY, KIRKLAND, QC, H9H 4M7
Order Desk:   800-663-8888
Technical Services Canada:   800-461-0917
Technical Services USA:   800-366-5288
Website:   www.zoetis.ca
Every effort has been made to ensure the accuracy of the Apoquel 5.4 mg tablets information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the Canadian product label or package insert.

Copyright © 2016 North American Compendiums. Updated: 2016-10-31

Hide